Postherpetic Neuralgia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

A shingles survivor's advice to the middle-aged: Get the vaccine - Philly.com



Philly.com
 
A shingles survivor's advice to the middle-aged: Get the vaccine 
Philly.com
The most common complication of shingles is post-herpetic neuralgia (PHN), severe pain in the areas where the shingles rash occurs. About 1 in 5 people with shingles will get PHN, estimates the CDC. The risk of PHN also increases with age. I was 59 ...

and more » 


Postherpetic Neuralgia Market Research Report 2017 to 2025 - Research of Market



Postherpetic Neuralgia Market Research Report 2017 to 2025 
Research of Market
Postherpetic Neuralgia-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Postherpetic Neuralgia. The report provides a complete understanding of the pipeline ...

and more » 


Watertown Daily Times | No excuses, people: get the new shingles ... - WatertownDailyTimes.com



California Healthline
 
Watertown Daily Times | No excuses, people: get the new shingles ... 
WatertownDailyTimes.com
Medical researchers and government health policymakers, a cautious lot, normally take pains to keep expectations modest when they're discussing some new ...
Shingles: Don't Let It Get You The Way It Got Me | Kaiser Health News Kaiser Health News

all 4 news articles » 


Vaccinations: Not just for kids, flu - Petoskey News-Review



Petoskey News-Review
 
Vaccinations: Not just for kids, flu 
Petoskey News-Review
NORTHERN MICHIGAN ? When most people hear the word ?vaccination,? they probably think of one of two kinds: The slew of vaccinations children receive (now into their teens) or the annual influenza vaccination that health officials advocate annually ...

and more » 


Postherpetic Neuralgia: Complete Product Development Cycle ... - Medgadget (blog)



Postherpetic Neuralgia: Complete Product Development Cycle ... 
Medgadget (blog)
Latest 'Postherpetic Neuralgia-Pipeline Insights' market research report: Get insight of all the latest development in the industry and affects of current.

and more » 


Postherpetic Neuralgia Pipeline Comparative Analysis 2017 - E News Access (press release)



Postherpetic Neuralgia Pipeline Comparative Analysis 2017 
E News Access (press release)
Postherpetic Neuralgia-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Postherpetic Neuralgia. The report provides a complete understanding of the pipeline ...

and more » 


New shingles vaccine touted as a breakthrough for older adults - Tampabay.com



Tampabay.com
 
New shingles vaccine touted as a breakthrough for older adults 
Tampabay.com
A sign marks the entrance to the federal Centers for Disease Control and Prevention in Atlanta, where an advisory committee last month approved a new ...

and more » 


No Excuses, People: Get the New Shingles Vaccine - New York Times



New York Times
 
No Excuses, People: Get the New Shingles Vaccine 
New York Times
What makes the new vaccine so promising, especially for older adults? * It provides better protection against shingles from the start. Though Zostavax, introduced in 2006, can reduce shingles cases by about half (and postherpetic neuralgia by two ...

 


Doctors encourage inoculation against painful shingles, laud new ... - CTV News



CTV News
 
Doctors encourage inoculation against painful shingles, laud new ... 
CTV News
A new vaccine called Shingrix, approved by Health Canada last month and available in January, has been shown in clinical trials to be more than 90 per cent ...
Local experts welcome new shingles vaccine | Local News ... Oneonta Daily Star

all 4 news articles » 


Analyzing Depomed (DEPO) and Par Pharmaceutical Companies (PRX) - The Ledger Gazette



Simply Wall St
 
Analyzing Depomed (DEPO) and Par Pharmaceutical Companies (PRX) 
The Ledger Gazette
Par Pharmaceutical Companies (NYSE: PRX) and Depomed (NASDAQ:DEPO) are both companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst ...
What Does Bollinger Band say about Depomed, Inc. (NASDAQ:DEPO)? The Oracle Examiner

all 20 news articles »